These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 23394826)

  • 1. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
    Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
    Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel.
    Mooiman KD; Maas-Bakker RF; Hendrikx JJ; Bank PC; Rosing H; Beijnen JH; Schellens JH; Meijerman I
    J Pharm Pharmacol; 2014 Jun; 66(6):865-74. PubMed ID: 24392691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba.
    Gurley BJ; Gardner SF; Hubbard MA; Williams DK; Gentry WB; Cui Y; Ang CY
    Drugs Aging; 2005; 22(6):525-39. PubMed ID: 15974642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions.
    Hermann R; von Richter O
    Planta Med; 2012 Sep; 78(13):1458-77. PubMed ID: 22855269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.
    Gurley BJ; Gardner SF; Hubbard MA; Williams DK; Gentry WB; Cui Y; Ang CY
    Clin Pharmacol Ther; 2002 Sep; 72(3):276-87. PubMed ID: 12235448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDR- and CYP3A4-mediated drug-herbal interactions.
    Pal D; Mitra AK
    Life Sci; 2006 Mar; 78(18):2131-45. PubMed ID: 16442130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herb-drug interactions: a literature review.
    Hu Z; Yang X; Ho PC; Chan SY; Heng PW; Chan E; Duan W; Koh HL; Zhou S
    Drugs; 2005; 65(9):1239-82. PubMed ID: 15916450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions with phytotherapeutics in oncology.
    Haefeli WE; Carls A
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):359-77. PubMed ID: 24387348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction.
    Mooiman KD; Maas-Bakker RF; Moret EE; Beijnen JH; Schellens JH; Meijerman I
    Drug Metab Dispos; 2013 Aug; 41(8):1494-504. PubMed ID: 23674609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical herbal interactions with conventional drugs: from molecules to maladies.
    Chen XW; Serag ES; Sneed KB; Liang J; Chew H; Pan SY; Zhou SF
    Curr Med Chem; 2011; 18(31):4836-50. PubMed ID: 21919844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical drugs that interact with St. John's wort and implication in drug development.
    Di YM; Li CG; Xue CC; Zhou SF
    Curr Pharm Des; 2008; 14(17):1723-42. PubMed ID: 18673195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug interactions with St John's wort : mechanisms and clinical implications.
    Mannel M
    Drug Saf; 2004; 27(11):773-97. PubMed ID: 15350151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of St. John's wort drug interactions revisited.
    Nicolussi S; Drewe J; Butterweck V; Meyer Zu Schwabedissen HE
    Br J Pharmacol; 2020 Mar; 177(6):1212-1226. PubMed ID: 31742659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.
    Mooiman KD; Maas-Bakker RF; Rosing H; Beijnen JH; Schellens JH; Meijerman I
    Biomed Chromatogr; 2013 Sep; 27(9):1107-16. PubMed ID: 23674377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interactions of drugs with St John's wort.
    Zhou S; Chan E; Pan SQ; Huang M; Lee EJ
    J Psychopharmacol; 2004 Jun; 18(2):262-76. PubMed ID: 15260917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interactions between herbal remedies and medicinal drugs.
    Ioannides C
    Xenobiotica; 2002 Jun; 32(6):451-78. PubMed ID: 12160480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
    Soleymani S; Bahramsoltani R; Rahimi R; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1047-1062. PubMed ID: 28885074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between herbal medicines and prescribed drugs: an updated systematic review.
    Izzo AA; Ernst E
    Drugs; 2009; 69(13):1777-98. PubMed ID: 19719333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.